$COLL
COLLEGIUM PHARMACEUTICAL, INC

2023 Q2 Form 10-Q Financial Statement

#000155837023008087 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $135.5M $144.8M
YoY Change 9.71% 72.85%
Cost Of Revenue $61.72M $67.37M
YoY Change -13.3% 91.08%
Gross Profit $73.83M $77.40M
YoY Change 40.99% 59.6%
Gross Profit Margin 54.47% 53.47%
Selling, General & Admin $38.19M $52.78M
YoY Change -7.42% -3.21%
% of Gross Profit 51.73% 68.18%
Research & Development $0.00 $0.00
YoY Change -100.0%
% of Gross Profit 0.0% 0.0%
Depreciation & Amortization $38.36M $817.0K
YoY Change 0.53% 14.27%
% of Gross Profit 51.96% 1.06%
Operating Expenses $38.19M $52.78M
YoY Change -7.42% -9.8%
Operating Profit $35.63M $24.63M
YoY Change 220.73% -345.9%
Interest Expense -$17.84M $21.43M
YoY Change -200.42% 267.47%
% of Operating Profit -50.05% 87.01%
Other Income/Expense, Net
YoY Change
Pretax Income $17.80M -$17.56M
YoY Change -367.79% 10.83%
Income Tax $4.790M -$131.0K
% Of Pretax Income 26.91%
Net Earnings $13.01M -$17.43M
YoY Change -350.57% 33.34%
Net Earnings / Revenue 9.6% -12.04%
Basic Earnings Per Share $0.38 -$0.51
Diluted Earnings Per Share $0.30 -$0.51
COMMON SHARES
Basic Shares Outstanding 34.59M 34.07M
Diluted Shares Outstanding 42.85M 34.32M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $325.5M $269.5M
YoY Change 165.21% 152.56%
Cash & Equivalents $283.7M $269.5M
Short-Term Investments $41.72M
Other Short-Term Assets $18.32M $16.80M
YoY Change 55.56% 60.76%
Inventory $26.03M $32.90M
Prepaid Expenses
Receivables $167.5M $179.1M
Other Receivables $0.00 $0.00
Total Short-Term Assets $537.3M $498.3M
YoY Change 31.12% 37.03%
LONG-TERM ASSETS
Property, Plant & Equipment $24.49M $18.88M
YoY Change 22.67% -6.55%
Goodwill $133.9M $133.9M
YoY Change 2.89% 1.78%
Intangibles $492.5M $530.0M
YoY Change -23.91% -23.72%
Long-Term Investments
YoY Change
Other Assets $25.73M $87.00K
YoY Change 38298.51% 12.99%
Total Long-Term Assets $676.6M $716.0M
YoY Change -19.05% -18.87%
TOTAL ASSETS
Total Short-Term Assets $537.3M $498.3M
Total Long-Term Assets $676.6M $716.0M
Total Assets $1.214B $1.214B
YoY Change -2.54% -2.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.420M $2.992M
YoY Change -63.48% -22.31%
Accrued Expenses $244.8M $24.43M
YoY Change 516.6% -40.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $183.3M $183.3M
YoY Change 51.72% 83.33%
Total Short-Term Liabilities $435.1M $412.7M
YoY Change 4.81% 10.47%
LONG-TERM LIABILITIES
Long-Term Debt $571.4M $615.0M
YoY Change -8.61% -8.02%
Other Long-Term Liabilities $6.630M $6.873M
YoY Change -12.76% -13.14%
Total Long-Term Liabilities $578.0M $621.9M
YoY Change -8.66% -8.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $435.1M $412.7M
Total Long-Term Liabilities $578.0M $621.9M
Total Liabilities $1.013B $1.035B
YoY Change -3.33% -1.48%
SHAREHOLDERS EQUITY
Retained Earnings -$285.8M -$298.8M
YoY Change 4.06% 10.9%
Common Stock $38.00K $38.00K
YoY Change 2.7% 5.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $200.8M $179.7M
YoY Change
Total Liabilities & Shareholders Equity $1.214B $1.214B
YoY Change -2.54% -2.56%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $13.01M -$17.43M
YoY Change -350.57% 33.34%
Depreciation, Depletion And Amortization $38.36M $817.0K
YoY Change 0.53% 14.27%
Cash From Operating Activities $99.72M $27.67M
YoY Change 146.53% -209.31%
INVESTING ACTIVITIES
Capital Expenditures $56.00K $176.0K
YoY Change -112.15% 62.96%
Acquisitions
YoY Change
Other Investing Activities -$41.66M
YoY Change
Cash From Investing Activities -$41.72M -$176.0K
YoY Change 8949.24% -99.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -45.24M 68.30M
YoY Change 88.75% -86.81%
NET CHANGE
Cash From Operating Activities 99.72M 27.67M
Cash From Investing Activities -41.72M -176.0K
Cash From Financing Activities -45.24M 68.30M
Net Change In Cash 12.77M 95.79M
YoY Change -20.31% -220.15%
FREE CASH FLOW
Cash From Operating Activities $99.72M $27.67M
Capital Expenditures $56.00K $176.0K
Free Cash Flow $99.67M $27.50M
YoY Change 143.61% -208.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
238000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-677000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-502000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-350000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1410000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1208000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3665000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3448000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001267565
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 coll Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q1 coll Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q1 coll Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q1 coll Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 coll Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q1 coll Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37372
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Collegium Pharmaceutical, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
VA
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
03-0416362
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Technology Center Drive
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Stoughton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02072
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
713-3699
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
COLL
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34594760
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269480000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173688000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
179127000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
183119000
CY2023Q1 us-gaap Inventory Net
InventoryNet
32895000
CY2022Q4 us-gaap Inventory Net
InventoryNet
46501000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16798000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16681000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
498300000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
419989000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18879000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19521000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6658000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6861000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
530002000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
567468000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
23969000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
23950000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
100000
CY2023Q1 us-gaap Goodwill
Goodwill
133857000
CY2022Q4 us-gaap Goodwill
Goodwill
133695000
CY2023Q1 us-gaap Assets
Assets
1214299000
CY2022Q4 us-gaap Assets
Assets
1174131000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2992000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3494000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24433000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36129000
CY2023Q1 coll Accrued Rebates Returns And Discounts Current
AccruedRebatesReturnsAndDiscountsCurrent
200902000
CY2022Q4 coll Accrued Rebates Returns And Discounts Current
AccruedRebatesReturnsAndDiscountsCurrent
230491000
CY2023Q1 us-gaap Loans Payable Current
LoansPayableCurrent
183333000
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
162500000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1042000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1112000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
412702000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
433726000
CY2023Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
353769000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
397578000
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
261222000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
140873000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6873000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7112000
CY2023Q1 us-gaap Liabilities
Liabilities
1034566000
CY2022Q4 us-gaap Liabilities
Liabilities
979289000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37816843
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34581020
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37084759
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33848936
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
540389000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
538073000
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3235823
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3235823
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
61924000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
61924000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298770000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281344000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
179733000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
194842000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1214299000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1174131000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144767000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83751000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-23504000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3993000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5006000
CY2023Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
29899000
CY2022Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
16332000
CY2023Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
37466000
CY2022Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
18923000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
67365000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35255000
CY2023Q1 us-gaap Gross Profit
GrossProfit
77402000
CY2022Q1 us-gaap Gross Profit
GrossProfit
48496000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3983000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52775000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54528000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
52775000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
58511000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
24627000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10015000
CY2023Q1 us-gaap Interest Expense
InterestExpense
21427000
CY2022Q1 us-gaap Interest Expense
InterestExpense
5831000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2747000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
4000
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-23504000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17557000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15842000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-131000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2773000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17426000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13069000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34319291
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33673912
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34319291
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33673912
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-17426000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-13069000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37466000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18923000
CY2023Q1 us-gaap Depreciation
Depreciation
817000
CY2022Q1 us-gaap Depreciation
Depreciation
715000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-46000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6038000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6035000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6135000
CY2023Q1 coll Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-105000
CY2022Q1 coll Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
158000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2287000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
913000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-13606000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-330000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12131000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6838000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
951170000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
421168000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
530002000
CY2023Q1 coll Increase Decrease In Accrued Rebates Returns And Discounts
IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts
-29589000
CY2022Q1 coll Increase Decrease In Accrued Rebates Returns And Discounts
IncreaseDecreaseInAccruedRebatesReturnsAndDiscounts
-21865000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27671000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25315000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
176000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
572069000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-572177000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
169000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
203000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3848000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3261000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7736000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3382000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
25000000
CY2022Q1 coll Proceeds From Term Note Modification
ProceedsFromTermNoteModification
517682000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5846000
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
235654000
CY2023Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
138638000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68297000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
517764000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
95792000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-79728000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
176235000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188973000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
272027000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109245000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
269480000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106698000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2547000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
272027000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109245000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
19499000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5833000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
743000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2114000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
148000
CY2023Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
434000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
956170000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
388702000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
567468000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24433000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36129000
CY2023Q1 coll Accrued Product Taxes And Fees Current
AccruedProductTaxesAndFeesCurrent
4821000
CY2022Q4 coll Accrued Product Taxes And Fees Current
AccruedProductTaxesAndFeesCurrent
4352000
CY2023Q1 us-gaap Revenue Practical Expedient Incremental Cost Of Obtaining Contract
RevenuePracticalExpedientIncrementalCostOfObtainingContract
true
CY2023Q1 coll Returns Policy Threshold Product Return Period
ReturnsPolicyThresholdProductReturnPeriod
P18M
CY2023Q1 coll Returns Policy Threshold Product Return Period Prior To Expiration
ReturnsPolicyThresholdProductReturnPeriodPriorToExpiration
P6M
CY2023Q1 coll Returns Policy Threshold Product Return Period After Expiration
ReturnsPolicyThresholdProductReturnPeriodAfterExpiration
P12M
CY2023Q1 coll Returns Policy Threshold Product Return Period
ReturnsPolicyThresholdProductReturnPeriod
P18M
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
144767000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83751000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2283000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1957000
CY2023Q1 coll Accrued Incentive Compensation Current
AccruedIncentiveCompensationCurrent
1486000
CY2022Q4 coll Accrued Incentive Compensation Current
AccruedIncentiveCompensationCurrent
2130000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17426000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13069000
CY2023Q1 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-17426000
CY2022Q1 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-13069000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34319291
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33673912
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34319291
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33673912
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q1 coll Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023Q1 coll Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1333000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1507000
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1225000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
6347000
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1051000
CY2023Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
550000000
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
5831000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5600000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
13347000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
24672000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13717000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
16229000
CY2023Q1 us-gaap Inventory Net
InventoryNet
32895000
CY2022Q4 us-gaap Inventory Net
InventoryNet
46501000
CY2023Q1 us-gaap Cost Direct Material
CostDirectMaterial
906000
CY2022Q4 us-gaap Goodwill
Goodwill
133695000
CY2023Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
162000
CY2023Q1 us-gaap Goodwill
Goodwill
133857000
CY2023Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
162000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37466000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
18923000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
112393000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
149859000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
149858000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
82678000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
7285000
CY2023Q1 coll Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
27929000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
530002000
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
7726000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13770000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
194842000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3848000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
169000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2023Q1 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units And Performance Share Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsAndPerformanceShareUnitsValue
-7736000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6035000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17426000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
179733000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202928000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3261000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
203000
CY2022Q1 coll Stock Withheld For Employee Taxes Upon Vesting Of Restricted Stock Units And Performance Share Units Value
StockWithheldForEmployeeTaxesUponVestingOfRestrictedStockUnitsAndPerformanceShareUnitsValue
-3382000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6135000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13069000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
196076000
CY2021Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
100000000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6035000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6135000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
61072000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2021 us-gaap Loss Contingency Claims Dismissed Number
LossContingencyClaimsDismissedNumber
13
CY2021Q4 us-gaap Loss Contingency Claims Settled Number
LossContingencyClaimsSettledNumber
27
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-131000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2773000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.175

Files In Submission

Name View Source Status
0001558370-23-008087-index-headers.html Edgar Link pending
0001558370-23-008087-index.html Edgar Link pending
0001558370-23-008087.txt Edgar Link pending
0001558370-23-008087-xbrl.zip Edgar Link pending
coll-20230331.xsd Edgar Link pending
coll-20230331x10q.htm Edgar Link pending
coll-20230331x10q001.jpg Edgar Link pending
coll-20230331xex31d1.htm Edgar Link pending
coll-20230331xex31d2.htm Edgar Link pending
coll-20230331xex32d1.htm Edgar Link pending
coll-20230331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
coll-20230331_cal.xml Edgar Link unprocessable
coll-20230331_def.xml Edgar Link unprocessable
coll-20230331_lab.xml Edgar Link unprocessable
coll-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
coll-20230331x10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending